Pylarify for charlotte HCC
Ended Awarded Last action
- Contract number
- 36C24625N0505
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 6
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $632,717
Award facts
- Opportunity
-
- 6505--Pylarify Injections Special Notice · Posted Dec 11, 2024
- Contract value 100% obligated
- $632,717.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$377,724 | |
| Original award | $1,010,442 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 6 (VISN 6) awarded a delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., on February 1, 2025, for the supply of PYLARIFY (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization. The contract is valued at $632,717.28 on a firm fixed-price basis with an ultimate completion date of January 31, 2026. Performance will occur at the contractor's manufacturing and distribution facility located in North Billerica, Massachusetts. This delivery order is issued without a set-aside designation and operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract framework that Progenics holds with the VA system.
This award represents a continuation of Progenics' established role as a critical supplier of radiopharmaceuticals to the federal healthcare system, supporting the VA's oncology diagnostic imaging programs across multiple medical centers within VISN 6. The company maintains substantial indefinite delivery vehicles and blanket purchase agreements with various Veterans Integrated Service Networks and the Defense Health Agency, with a major Federal Supply Schedule contract ceiling of $290 million extending through March 31, 2030. The current delivery order reflects routine procurement of essential diagnostic imaging supplies that enable federal healthcare providers to deliver advanced cancer detection capabilities to veterans.
Quick answers
Who was awarded contract 36C24625N0505?
36C24625N0505 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 6 (Veterans Health Administration) on February 1, 2025.
How much is contract 36C24625N0505 worth?
The government has obligated $632,717 on 36C24625N0505.
Is contract 36C24625N0505 an order under another contract?
Yes. 36C24625N0505 is a delivery order under 36C24625D0035, an indefinite delivery contract.
Was contract 36C24625N0505 competed?
The extent of competition for 36C24625N0505 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award